Understanding risk factors, screening, and treatment of postmenopausal osteoporosis.
Between 30% and 50% of American women will endure a clinical fracture during their lifetime due to the loss of bone mineral density that occurs with menopausal estrogen loss. This article is part one in a two-part series on osteoporosis. Part two will appear in the August 2008 issue of ORTHOPEDICS.
Johnson
Nicole K
NK
University of Kentucky Health-Care, Lexington, Kentucky 40536-0293, USA.
Clifford
Timothy
T
Smith
Kelly M
KM
D015502:Absorptiometry, Photon; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D012307:Risk Factors; D019379:Teriparatide / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019379:Teriparatide; D020849:Raloxifene Hydrochloride; D002116:Calcitonin